Format

Send to

Choose Destination
Prim Care Respir J. 2010 Sep;19(3):266-73. doi: 10.4104/pcrj.2010.00040.

Observational study comparing intranasal mometasone furoate with oral antihistamines for rhinitis and asthma.

Author information

1
Academic Centre of Primary Care, University of Aberdeen, Aberdeen, UK. david@respiratoryresearch.org

Abstract

AIMS:

Retrospective database study comparing upper and lower airway-related outcomes for patients with rhinitis and co-morbid asthma receiving mometasone furoate--an intranasal corticosteroid with low systemic bioavailability--or an oral antihistamine.

METHODS:

395 patients prescribed intranasal mometasone were matched on 10 demographic and respiratory-related criteria in a 1:2 ratio to 790 patients prescribed oral antihistamine. Asthma and rhinitis control were assessed over one year using predefined composite proxy measures.

RESULTS:

Asthma control was achieved by 309/395 (78.2%) versus 580/790 (73.4%; p=0.071) patients in the mometasone and antihistamine cohorts, respectively. Rhinitis control was achieved by 293 (74.2%) versus 539 (68.2%; p=0.035), respectively. The adjusted odds ratios for antihistamines, relative to mometasone, were 0.71 (95% CI, 0.52-0.98) for achieving asthma control and 0.74 (95% CI, 0.56-0.97) for achieving rhinitis control.

CONCLUSIONS:

Patients with rhinitis and co-morbid asthma initiating rhinitis therapy achieved significantly better upper as well as lower airway outcomes with intranasal mometasone than with oral antihistamine.

PMID:
20571732
DOI:
10.4104/pcrj.2010.00040
[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for Primary Care Respiratory Society UK
Loading ...
Support Center